[HTML][HTML] Natural killer cells and T cells in hepatocellular carcinoma and viral hepatitis: current status and perspectives for future immunotherapeutic approaches

SG Kalathil, Y Thanavala - Cells, 2021 - mdpi.com
Natural killer (NK) cells account for 25–50% of the total number of hepatic lymphocytes,
which implicates that NK cells play an important role in liver immunity. The frequencies of …

[HTML][HTML] The role of NLRP3 inflammasome in hepatocellular carcinoma

H Zhao, Y Zhang, Y Zhang, C Chen, H Liu… - Frontiers in …, 2023 - frontiersin.org
Inflammasomes play an important role in innate immunity. As a signal platform, they deal
with the excessive pathogenic products and cellular products related to stress and injury. So …

[HTML][HTML] TGFβ drives NK cell metabolic dysfunction in human metastatic breast cancer

K Slattery, E Woods, V Zaiatz-Bittencourt… - … for ImmunoTherapy of …, 2021 - ncbi.nlm.nih.gov
Background Natural killer (NK) cells provide important immune protection from cancer and
are a key requirement for particular immunotherapies. There is accumulating evidence that …

[HTML][HTML] A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC

K Du, Y Li, J Liu, W Chen, Z Wei, Y Luo, H Liu, Y Qi… - Molecular Therapy, 2021 - cell.com
Glypican-3 (GPC3) is a well-characterized hepatocellular carcinoma (HCC)-associated
antigen, yet anti-GPC3 therapies have achieved only minimal clinical progress. CD47 is a …

[HTML][HTML] EpCAM-high liver cancer stem cells resist natural killer cell–mediated cytotoxicity by upregulating CEACAM1

DJ Park, PS Sung, JH Kim, GW Lee… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background Natural killer (NK) cells can recognize and kill cancer cells directly, but their
activity can be attenuated by various inhibitory molecules expressed on the surface. The …

[HTML][HTML] Safety and efficacy of sintilimab and anlotinib as first line treatment for advanced hepatocellular carcinoma (KEEP-G04): a single-arm phase 2 study

X Chen, W Li, X Wu, F Zhao, D Wang, H Wu… - Frontiers in …, 2022 - frontiersin.org
Purpose: Immune checkpoint inhibitors plus antiangiogenic tyrosine kinase inhibitors may
offer a first-line treatment for advanced hepatocellular carcinoma (HCC). In this phase 2 trial …

Neutrophil-mediated mechanisms of damage and in-vitro protective effect of colchicine in non-vascular Behçet's syndrome

A Bettiol, M Becatti, E Silvestri… - Clinical & …, 2021 - academic.oup.com
Behçet's syndrome (BS) is a systemic vasculitis with several clinical manifestations.
Neutrophil hyperactivation mediates vascular BS pathogenesis, via both a massive reactive …

[HTML][HTML] Intratumor regulatory noncytotoxic NK cells in patients with hepatocellular carcinoma

A Zecca, V Barili, D Rizzo, A Olivani, E Biasini… - Cells, 2021 - mdpi.com
Previous studies support the role of natural killer (NK) cells in controlling hepatocellular
carcinoma (HCC) progression. However, ambiguity remains about the multiplicity and the …

[HTML][HTML] Tumor microenvironment in primary liver tumors: A challenging role of natural killer cells

MA Polidoro, J Mikulak, V Cazzetta, A Lleo… - World journal of …, 2020 - ncbi.nlm.nih.gov
In the last years, several studies have been focused on elucidate the role of tumor
microenvironment (TME) in cancer development and progression. Within TME, cells from …

[HTML][HTML] Radioembolization for the treatment of hepatocellular carcinoma

HC Kim - Clinical and molecular hepatology, 2017 - ncbi.nlm.nih.gov
Transarterial radioembolization (TARE) with yttrium 90 (90 Y), an intra-arterial procedure
performed by interventional radiologists, has begun being utilized in managing …